MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sagent Pharmaceuticals Company Profile (NASDAQ:SGNT)

Consensus Ratings for Sagent Pharmaceuticals (NASDAQ:SGNT) (?)
Ratings Breakdown: 3 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $17.67 (17.62% upside)

Analysts' Ratings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Show:
DateFirmActionRatingPrice TargetActions
6/17/2016Jefferies GroupReiterated RatingHold$13.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Bank of AmericaReiterated RatingHold$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016RBC CapitalReiterated RatingOutperform$28.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Piper JaffrayReiterated RatingOverweight$23.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/12/2016Deutsche BankLower Price TargetBuy$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2015Raymond JamesReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2014Needham & Company LLCDowngradeBuy -> Hold$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/25/2014S&P Equity ResearchDowngradeBuy -> Neutral$25.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/3/2016Q1$0.01($0.15)$74.30 million$67.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/16/2016Q415($0.02)($0.55)$78.13 million$83.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.07)$0.01$73.84 million$75.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215$0.05($0.01)$83.28 million$77.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115$0.04$0.04$80.63 million$82.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414$0.01$0.91$76.20 million$84.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.04)$0.08$64.01 million$65.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2014Q214($0.01)$0.09$67.14 million$69.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.02)$0.16$65.66 million$70.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2014Q4($0.01)$0.11$60.25 million$64.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013($0.03)$0.10ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013$0.46$59.27 million$59.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2013Q1 2013($0.03)$0.34$55.31 million$60.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.20)($0.13)$48.60 million$49.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Sagent Pharmaceuticals (NASDAQ:SGNT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.06$0.06$0.06
Q2 20161($0.19)($0.19)($0.19)
Q3 20161$0.19$0.19$0.19
Q4 20161$0.35$0.35$0.35
(Data provided by Zacks Investment Research)
Dividend History for Sagent Pharmaceuticals (NASDAQ:SGNT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Sagent Pharmaceuticals (NASDAQ:SGNT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
4/21/2016Ventures Fund V L.P. VivoMajor ShareholderSell2,005$13.55$27,167.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/4/2015Ventures Fund V L.P. VivoMajor ShareholderSell603,177$15.72$9,481,942.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2015Vivo Ventures Vi, LlcMajor ShareholderSell67,283$16.32$1,098,058.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Vivo Ventures Vi, LlcMajor ShareholderSell93,523$16.87$1,577,733.01View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Morgan Stanley Investment ManaMajor ShareholderSell78,041$26.16$2,041,552.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Morgan Stanley Investment ManaMajor ShareholderSell211,883$25.61$5,426,323.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2015Morgan Stanley Investment ManaMajor ShareholderSell69,316$25.23$1,748,842.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Morgan Stanley Investment ManaMajor ShareholderSell125,000$25.16$3,145,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Morgan Stanley Investment ManaMajor ShareholderSell100,000$25.51$2,551,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014Robert J FlanaganDirectorSell16,000$31.56$504,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/7/2014Robert J FlanaganDirectorSell8,000$31.15$249,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Robert J FlanaganDirectorSell16,000$30.01$480,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2014Robert J FlanaganDirectorSell8,000$30.30$242,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Robert J FlanaganDirectorSell16,000$28.30$452,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Robert J FlanaganDirectorSell8,000$28.35$226,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2014Robert J FlanaganDirectorSell16,000$27.19$435,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Robert J FlanaganDirectorSell8,000$27.30$218,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Robert J FlanaganDirectorSell16,000$24.39$390,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/31/2014Robert J FlanaganDirectorSell16,000$25.60$409,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Robert J FlanaganDirectorSell16,000$26.18$418,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/2/2014Robert J FlanaganDirectorSell16,000$26.51$424,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Robert J FlanaganDirectorSell16,000$23.37$373,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Robert J FlanaganDirectorSell16,000$22.17$354,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Robert FlanaganDirectorSell8,000$22.02$176,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/27/2014Michael LogerfoInsiderSell2,021$21.43$43,310.03View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2013Morgan Stanley Investment Manamajor shareholderSell47,826$20.27$969,433.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2013Morgan Stanley Investment Manamajor shareholderSell67,965$20.37$1,384,447.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2013Morgan Stanley Investment Manamajor shareholderSell48,124$21.30$1,025,041.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2013Morgan Stanley Investment Manamajor shareholderSell119,557$21.83$2,609,929.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2013Morgan Stanley Investment Manamajor shareholderSell88,885$22.53$2,002,579.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Frank KungDirectorSell1,161,717$21.25$24,686,486.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Jeffrey YordonCEOSell85,813$20.03$1,718,834.39View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2013Vivo Ventures Vi, Llcmajor shareholderSell622,700$21.25$13,232,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Lorin DrakeVPSell1,000$23.69$23,690.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Sagent Pharmaceuticals (NASDAQ:SGNT)
DateHeadline
06/23/16 12:54 PMETF’s with exposure to Sagent Pharmaceuticals, Inc. : June 23, 2016 -
06/23/16 08:59 AMSAGENT PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
06/22/16 11:05 AMSagent Pharmaceuticals Inc. (SGNT) Jumps 6.46% on June 20 - Equities.com
06/20/16 07:54 AMThis Weeks Broker Views For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Fiscal Standard
06/19/16 10:06 AMJefferies & Co maintained Sagent Pharmaceuticals (NASDAQ:SGNT) as 'Hold' With 15 PT - FTSE News
06/17/16 06:04 PMSagent Pharmaceuticals, Inc. (SGNT) – Jefferies Holds Rating And Sets New Price Target
06/16/16 10:45 AMSagent Pharmaceuticals (SGNT) to Acquire ANDA Portfolio from Teva Pharma (TEVA) in $40M Deal - StreetInsider.com
06/16/16 07:39 AMSagent Pharmaceuticals Acquires Product Portfolio From Teva Pharmaceutical Industries Ltd. - [at noodls] - SCHAUMBURG, Ill., June 16, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading provider of affordable pharmaceuticals to the hospital market, today announced that it has entered ...
06/16/16 07:36 AMBRIEF-Sagent Pharmaceuticals buys product portfolio from Teva Pharmaceutical - * Sagent Pharmaceuticals acquires product portfolio from Teva Pharmaceutical Industries Ltd
06/16/16 07:16 AMSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial -
06/13/16 05:55 PMSagent Pharmaceuticals : Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter
06/13/16 05:09 PMSagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Oxacillin for Injection, USP, 10g Due to Presence of Dark Particulate Matter - [at noodls] - SCHAUMBURG, Ill., June 13, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Oxacillin for Injection, USP, 10g (NDC 25021-163-69) Lot OXT515 ...
06/10/16 04:17 PMSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 06:52 PMSAGENT PHARMACEUTICALS INC. (NASDAQ:SGNT) Financial Condition Compared to S&P 500 - CML News
06/05/16 09:03 AMSagent Pharmaceuticals' (SGNT) Overweight Rating Reiterated at Piper Jaffray - Let Me Know About This
06/04/16 06:27 PMSagent Pharmaceuticals' (SGNT) Hold Rating Reiterated at JPMorgan Chase & Co. - Let Me Know About This
06/04/16 09:21 AMAnalysts watching two Stocks: Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) , Ophthotech Corporation (NASDAQ ... - Street Updates
06/03/16 07:01 PMSagent Pharmaceuticals Inc (SGNT) Stock Rating Reaffirmed by JPMorgan Chase & Co. - Let Me Know About This
05/29/16 10:03 PMSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Impact Score At 0 - Stocks Daily - Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Impact Score At 0Stocks DailyAlpha One explored various online articles released on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), and it set a daily sentiment score of 0 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) EPS Estimate At $0.15Enterprise Leaderall 3 news articles »
05/26/16 05:50 AMSagent Pharmaceuticals Incorporated (NASDAQ:SGNT) Short Interest Decreased By 1.12% - Wall Street Hints and News - Sagent Pharmaceuticals Incorporated (NASDAQ:SGNT) Short Interest Decreased By 1.12%Wall Street Hints and NewsThe short interest to Sagent Pharmaceuticals Incorporated's float is 8.57%. The stock decreased 0.66% or $0.08 during the last trading session, hitting $12.01. About 313,832 shares traded hands. Sagent Pharmaceuticals Inc (NASDAQ:SGNT) has declined ...and more »
05/25/16 09:27 PMBroker Roundup For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Share Trading News - Broker Roundup For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)Share Trading NewsThe share price of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) was up +0.00% during the last trading session, with a day high of 0.00. 0 shares were traded on Sagent Pharmaceuticals, Inc.'s last session. The stock's 50 day moving average is 11.97 and ...and more »
05/25/16 07:59 AMSagent Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SGNT-US : May 25, 2016 -
05/24/16 11:13 AMEarnings Review and Stock Rundown for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Wall Street Hints and News - Earnings Review and Stock Rundown for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT ...and more »
05/20/16 10:53 AMIJR's Underlying Holdings Could Mean 14% Gain Potential - AMRI), Sagent Pharmaceuticals Inc (Symbol: SGNT), and TTM Technologies Inc (Symbol: TTMI). Although AMRI has traded at a recent price of $13.57/share, the average analyst target is 79.31% higher at $24.33/share. Similarly, SGNT has 58.41% upside from the ...
05/19/16 10:36 AMRevenue Update on Sagent Pharmaceuticals Inc(NASDAQ:SGNT) - Trade Calls - Revenue Update on Sagent Pharmaceuticals Inc(NASDAQ:SGNT)Trade CallsSagent Pharmaceuticals Inc(NASDAQ:SGNT) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 3, 2016. Company reported revenue of $67.80M. Analysts estimated a revenue of $74.30M. Earnings ...
05/17/16 07:29 PMShare Recap and Earnings Focus on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Wall Street Hints and News - Share Recap and Earnings Focus on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Sagent Pharmaceuticals, Inc.and more »
05/17/16 07:29 PMNext Weeks Broker Price Targets For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - Share Trading News - Next Weeks Broker Price Targets For Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)Share Trading News05/04/2016 – Sagent Pharmaceuticals, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 20 price target on the stock. 02/17/2016 – Sagent Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at ...Were Analysts Bullish Sagent Pharmaceuticals Inc (NASDAQ:SGNT) This Week?Wall Street Hints and Newsall 20 news articles »
05/17/16 07:29 PMSagent Pharmaceuticals Inc. (SGNT) Jumps 6.02% on May 16 - Equities.com - Sagent Pharmaceuticals Inc. (SGNT) Jumps 6.02% on May 16Equities.comSagent Pharmaceuticals Inc. (SGNT) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 6.02% to $11.45, representing a gain of $0.65 per share. Some 383,235 shares traded hands on 2,689 trades, compared with ...
05/17/16 11:35 AMWere Analysts Bullish Sagent Pharmaceuticals Inc (NASDAQ:SGNT) This Week? - Wall Street Hints and News - Were Analysts Bullish Sagent Pharmaceuticals Inc (NASDAQ:SGNT) This Week?Wall Street Hints and NewsOut of 8 analysts covering Sagent Pharmaceuticals (NASDAQ:SGNT), 4 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 44% are positive. Sagent Pharmaceuticals has been the topic of 7 analyst reports since August 5, 2015 according to ...and more »
05/13/16 04:13 PMSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers -
05/12/16 05:18 AMConsensus Rating Review for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - B.O.D.Y Confidential - Consensus Rating Review for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 2.13 on shares of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/10/16 12:04 PMSAGENT PHARMACEUTICALS, INC. Financials -
05/09/16 11:22 AMSagent Pharmaceuticals, Inc. :SGNT-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/07/16 12:37 AMSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Updated Broker Price Targets - Share Trading News - Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT). The latest reports which are currently in issue on Thursday 5th of May state 0 analysts have a rating of “strong buy”, 0 ...Sagent Pharmaceuticals Inc (SGNT) Stock Rating Lowered by Zacks Investment ResearchWeb Breaking NewsSagent Pharmaceuticals Bests Q1 Loss Expectations, Misses Revenue (NASDAQ:SGNT)Sonoran Weekly ReviewWhat's Propelling Sagent Pharmaceuticals Inc to Reach 52-Week Low?Franklin IndependentSeeking Alpha -Finance Daily -GlobeNewswire (press release)all 23 news articles »
05/05/16 10:30 PMSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Boasts An Average Rating Of 5 - RealistInvestor.com - Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Boasts An Average Rating Of 5RealistInvestor.comAlpha One applies algorithm-based analytics for assessing a stock sentiment as per the published released on web channels. In this evaluation process, the group accesses the most relevant news platforms on a daily basis. Sagent Pharmaceuticals, Inc.and more »
05/05/16 10:30 PMSagent Pharmaceuticals Inc. (SGNT) is Trading Higher on Unusual Volume for May 03 - Equities.com - Sagent Pharmaceuticals Inc. (SGNT) is Trading Higher on Unusual Volume for May 03Equities.comSagent Pharmaceuticals Inc. (SGNT) experienced unusually high volume on May. 03, as the stock gained 3.4% to a closing price of $12.16. The stock saw 672,966 shares trade hands over the course of the day on 4,608 trades. Given that the stock's average ...Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Updated Broker Price TargetsShare Trading NewsSagent Pharmaceuticals Inc (SGNT) Stock Rating Lowered by Zacks Investment ResearchWeb Breaking NewsRecently Changed Price Targets On Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)Risers & FallersSonoran Weekly Review -B.O.D.Y Confidential -Franklin Independentall 24 news articles »
05/05/16 10:30 PMSagent Pharmaceuticals Inc. (SGNT) Drops 6.33% on May 04 - Equities.com - Sagent Pharmaceuticals Inc. (SGNT) Drops 6.33% on May 04Equities.comSagent Pharmaceuticals Inc. (SGNT) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 6.33% to $11.39, a loss of $-0.77 per share. Starting at an opening price of $11.99 a share, the stock traded between $11.38 and ...and more »
05/04/16 02:36 AMAverage Analyst Rating for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) - B.O.D.Y Confidential - Average Analyst Rating for Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 2.13 on Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/03/16 03:01 PMEdited Transcript of SGNT earnings conference call or presentation 3-May-16 1:00pm GMT -
05/03/16 07:02 AMSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements -
05/03/16 06:52 AMSagent reports 1Q loss -
05/03/16 06:50 AMSagent Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - Company Affirms 2016 Full Year Guidance Substantial Progress against Long-Term Growth Strategy; SCHAUMBURG, Ill., May 03, 2016 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT), a leading ...
05/03/16 06:32 AM7:32 am Sagent Pharma beats by $0.02, misses on revs; guides FY16 revs in-line -
05/03/16 06:07 AMQ1 2016 Sagent Pharmaceuticals Inc Earnings Release - Before Market Open -
04/27/16 10:32 PMMust see these stocks: Sagent Pharmaceuticals Inc (SGNT), Pacific Biosciences of California (PACB) - News Oracle - Must see these stocks: Sagent Pharmaceuticals Inc (SGNT), Pacific Biosciences of California (PACB)News OracleSagent Pharmaceuticals Inc (NASDAQ:SGNT) surged 0.08% yesterday and closed at $11.94. The company's market capitalization is at $190.08 Million with an average trading volume of 380,065.00. The total number of Outstanding Shares Held by the ...and more »
04/27/16 05:33 AMSagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Share Rating Recap - B.O.D.Y Confidential - Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) Share Rating RecapB.O.D.Y ConfidentialShares of Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/26/16 08:28 PMSagent Pharmaceuticals Inc. (SGNT) Drops 7.09% on April 25 - Equities.com - Sagent Pharmaceuticals Inc. (SGNT) Drops 7.09% on April 25Equities.comSagent Pharmaceuticals Inc. (SGNT) was one of the Russell 2000's biggest losers for Monday April 25 as the stock slid 7.09% to $11.93, a loss of $-0.91 per share. Starting at an opening price of $12.85 a share, the stock traded between $11.80 and $13 ...and more »
03/23/16 04:18 PMSAGENT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial S -
03/01/16 11:30 AMSagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg Per 100mL Due to the Discovery of an Out of Specification Impurity Result Detected During Routine Quality Testing - [GlobeNewswire] - SCHAUMBURG, Ill., March 01, 2016-- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of one lot of Fluconazole Injection, USP, 200 mg per 100 mL flexible container bag Lot 40608 ...
02/25/16 07:00 AMSagent Pharmaceuticals Names Frank Harmon Executive Vice President Global Operations - [GlobeNewswire] - SCHAUMBURG, Ill., Feb. 25, 2016-- Sagent Pharmaceuticals, Inc., a leading provider of affordable pharmaceuticals to the hospital market, announced the hiring of Frank Harmon as Executive Vice President, ...
About Sagent Pharmaceuticals

Sagent Pharmaceuticals logoSagent Pharmaceuticals, Inc. (Sagent), formerly Sagent Holding Co., is an injectable pharmaceutical company that develops and sources products that the Company sells primarily in the United States. Sagent focuses primarily on generic injectable pharmaceuticals. Sagent offers its customers a range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled, ready-to-use syringes, medical devices and premix bags. As of October 31, 2010, Sagent marketed 21 products. The Company has a 50/50 joint venture known as Sagent Strides LLC (Sagent Strides) with a subsidiary of Strides Arcolab Limited (Strides), which is an Indian manufacturer of finished pharmaceutical products.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SGNT
  • CUSIP: 78669210
Key Metrics:
  • Previous Close: $15.02
  • 50 Day Moving Average: $12.90
  • 200 Day Moving Average: $13.64
  • P/E Ratio: N/A
  • P/E Growth: 1.86
  • Market Cap: $493.23M
  • Current Quarter EPS Consensus Estimate: $0.25 EPS
Additional Links:
Sagent Pharmaceuticals (NASDAQ:SGNT) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha